GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Ascelia Pharma ACE.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.53

-5.73%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ascelia Pharma

Its shares trade on Nasdaq Stockholm under the ticker ACE.ST. It has been listed since 13 March 2019.

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Mar 2019
Employees
24
Website
ascelia.com ↗

Leadership

Pay as last reported

  • Mr. Peter BensonChairman of the Board, since 2017SEK 248
  • Mr. Magnus CorfitzenChief Executive OfficerSEK 2.6m
  • Ms. Julie Waras BrogrenDeputy Chief Executive Officer, Chief Compliance Officer
  • Dr. Carl BjartmarChief Medical Officer
  • Ms. Marianne KockDirector
  • Mr. Hans MaierDirector
  • Ms. Lauren BarnesIndependent Director
  • Ms. Helena WennerstromIndependent Director
  • Mr. Mikael WidellHead of Investor Relations & Communication, since 2018

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Ascelia Pharma AB employs 24 full-time staff members in Malmo.
  • Mangoral has completed phase II clinical studies for liver metastases detection.
  • The pipeline includes Oncoral, a tablet formulation of irinotecan for gastric cancer.

Weaknesses

  • The company has only 24 employees, limiting operational capacity significantly.
  • Ascelia Pharma AB is headquartered in Malmo, which may restrict talent access.
  • The firm relies on two main drug candidates for its pipeline.

Opportunities

  • Mangoral targets patients with impaired kidneys needing liver MRI detection.
  • Oncoral addresses the unmet medical need in gastric cancer treatment.
  • Ascelia Pharma AB can expand its pipeline with derisked drug candidates.

Threats

  • Clinical trial failures for Mangoral or Oncoral could halt progress.
  • Competitors in biotechnology may develop superior liver imaging or cancer drugs.
  • Regulatory hurdles for phase III studies might delay product availability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.